Home / Stocks / Alivus Life Sciences Ltd
ALIVUS

Alivus Life Sciences Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,449.9

Change

+5.2 (0.36%)

Open

₹1,448.0

Prev. Close

₹1,444.7

Day High

₹1,467.7

Day Low

₹1,441.5

Volume Analysis

Traded

211,425

Delivered

130,295

Delivery %

61.63%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (31.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,490.76 ₹1,479.23 ₹1,464.56 ₹1,453.03 ₹1,438.36 ₹1,426.83 ₹1,412.16
Fibonacci ₹1,479.23 ₹1,469.22 ₹1,463.04 ₹1,453.03 ₹1,443.02 ₹1,436.84 ₹1,426.83
Camarilla ₹1,457.11 ₹1,454.7 ₹1,452.3 ₹1,453.03 ₹1,447.5 ₹1,445.1 ₹1,442.7

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+59.75%

1 Week

+0.43%

1 Month

+15.26%

3 Months

+7.33%

6 Months

+39.55%

1 Year

+59.35%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Company Overview

Sector

Healthcare

Market Cap

₹17,803 Cr

P/E (TTM)

50.6

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Alivus Life Sciences Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (31.0%); promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

64/100 — Average

Data confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Valuation

3

Cash Flow

0

Corporate Governance

43

Momentum

83

Institutional Ownership

60

Business Quality

96

Risk & Volatility

91

Liquidity

77

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

On November 11, 2026, Alivus acquired 65.01% of IQGEN-X Pharma; remaining stake to be acquired.

Alivus executed SHA for 76% IQGEN-X stake, with option to acquire remaining 24% in five years.

Nirma sold 36.8 lakh Alivus shares on 6 Nov, cutting holding to 71.74%.

Please find attached herewith submission with respect to transcript of the earning call.

Alivus Life Sciences schedules one-on-one investor meetings with Avarta Capital, BOI Mutual Fund and Bandhan Mutual Fund on Nov 6 and 12, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 595 573 537 589 507 642 650 602 588 673 689 640 682
Expenses + 428 400 395 429 373 452 451 430 409 442 475 429 417
Operating Profit 167 173 141 159 134 190 198 172 179 231 215 212 265
OPM % 28.0% 30.0% 26.0% 27.0% 27.0% 30.0% 31.0% 29.0% 30.0% 34.0% 31.0% 33.0% 39.0%
Other Income + 5 2 3 5 9 10 10 9 15 -12 23 22 20
Interest 0 0 0 0 0 0 1 1 1 1 1 1 1
Depreciation 13 13 15 14 15 15 16 17 18 20 20 21 22
Profit before tax 159 161 130 150 127 185 191 163 174 198 216 212 262
Tax % 25.0% 26.0% 24.0% 26.0% 25.0% 26.0% 26.0% 25.0% 25.0% 24.0% 25.0% 25.0% 25.0%
Net Profit + 119 119 98 111 95 137 142 122 130 150 163 160 197
EPS in Rs 10 10 8 9 8 11 12 10 11 12 13 13 16
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 17 6 -14 2 -15 12 21 2 16 5 6 6 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021
Sales + 0 886 1,537 1,885
Expenses + 0 639 1,065 1,294
Operating Profit 0 248 472 591
OPM % -4.0% 28.0% 31.0% 31.0%
Other Income + 0 0 12 1
Interest 0 1 34 88
Depreciation 0 19 29 33
Profit before tax 0 228 421 471
Tax % 4,200.0% 14.0% 26.0% 25.0%
Net Profit + 0 196 313 352
EPS in Rs 0 18 29 33
Dividend Payout % 0.0% 0.0% 0.0% 0.0%
Sales growth — — 73 23

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021
Reserves -1 — — —
Borrowings + 0 — — —
Other Liabilities + 1 — — —
Total Liabilities 0 — — —
Fixed Assets + 0 — — —
CWIP 0 — — —
Investments 0 — — —
Other Assets + 0 — — —
Total Assets 0 — — —
Equity Capital 0 — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021
Cash from Operating Activity + 0 — — —
Cash from Investing Activity + 0 — — —
Cash from Financing Activity + 0 — — —
Net Cash Flow 0 — — —
Free Cash Flow 0 — — —
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 4,800 — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 82.85% → 74.85%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 11.84% 10.73% 10.76% 12.99% 13.4% 13.25% 13.03% 12.79% 12.89% 12.55% 12.42% 12.19%
Promoters 82.85% 82.85% 82.85% 75.0% 75.0% 74.99% 74.94% 74.91% 74.91% 74.87% 74.87% 74.85%
FII 4.57% 5.01% 4.81% 7.85% 6.74% 6.57% 6.42% 6.84% 5.08% 5.3% 5.54% 5.93%
DII 0.74% 1.41% 1.57% 4.16% 4.86% 5.19% 5.62% 5.47% 7.13% 7.27% 7.18% 7.03%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Alivus Life Sciences Ltd (this stock) 17,803 50.6 — —
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%
Syngene International Ltd 17,935 67.5 3.7 7.78%
Pfizer Ltd 17,601 115.0 12.74 19.8%
Cohance Lifesciences Ltd 17,511 359.0 4.49 4.89%
Dr Agarwals Health Care L 17,460 97.5 7.8 6.41%
Eris Lifesciences Limited 18,448 24.7 4.45 18.7%

Which Mutual Funds Hold Alivus Life Sciences Ltd?

Frequently Asked Questions about Alivus Life Sciences Ltd

Community Sentiment

What are other investors saying about Alivus Life Sciences Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.